(Q36271114)

13 August 2017

title

Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma (English)

1 reference

13 August 2017

1 reference

Evangelos Terpos

1

1 reference

13 August 2017

Katayoun Rezvani

2

1 reference

13 August 2017

Supratik Basu

3

1 reference

13 August 2017

Alison E Milne

4

1 reference

13 August 2017

Peter E Rose

5

1 reference

13 August 2017

Geoffrey L Scott

6

1 reference

13 August 2017

Amin Rahemtulla

7

1 reference

13 August 2017

Diana Samson

8

1 reference

13 August 2017

Jane F Apperley

9

1 reference

13 August 2017

publication date

1 November 2005

1 reference

European Journal of Haematology

13 August 2017

published in

1 reference

13 August 2017

volume

75

1 reference

13 August 2017

issue

5

1 reference

13 August 2017

page(s)

376-383

1 reference

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00531.X

Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00531.X

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00531.X

Graft-versus-myeloma after donor leukocyte infusion: maintenance of marrow remission but extramedullary relapse with plasmacytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00531.X

Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00531.X

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00531.X

Thalidomide is effective for extramedullary relapse of multiple myeloma post-allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00531.X

Features of extramedullary and extraosseous multiple myeloma: a report of 19 patients from a single center

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00531.X

Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00531.X

Graft vs. host disease and graft vs. myeloma effect after non-myeloablative allogeneic transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00531.X

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00531.X

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00531.X

Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00531.X

Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00531.X

Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00531.X

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00531.X

Discrepancy between serological complete remission and concomitant new bone lytic lesions after infusion of escalating low doses of donor lymphocytes in multiple myeloma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00531.X

Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00531.X

Prognostic value of angiogenesis in solitary bone plasmacytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00531.X

10.1111/J.1600-0609.2005.00531.X

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference